Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Rhabdoid Tumor 1Neuroectodermal Tumors, Primitive 1Meningeal Carcinomatosis 1Medulloblastoma 1Lung Neoplasms 1Infratentorial Neoplasms 1Ependymoma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Cyclophosphamide 6Vincristine 3Temozolomide 3Radiotherapy 3Cisplatin 3Automobiles 3fludarabine 2Etoposide 2Eflornithine 2Carboplatin 2omburtamab I-131 1ibrutinib 1gallium Ga 68 dotatate 1etoposide phosphate 1belzutifan 1Zoledronic Acid 1Thiotepa 1Tamoxifen 1Standard of Care 1Radiotherapy, Image-Guided 1Pemetrexed 1ONC206 1Nivolumab 1Mesna 1Maintenance Chemotherapy 1Lomustine 1Isotretinoin 1Induction Chemotherapy 1Hydrocortisone 1HhAntag691 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroectodermal Tumors, Primitive × Craniospinal Irradiation × 1 year × Clear all
NCT01878617 2025-11-13

A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma

St. Jude Children's Research Hospital

Phase 2 Active not recruiting
660 enrolled
CNS

Brain Neoplasms, Medulloblastoma, Infratentorial Neoplasms, Neuroectodermal Tumors, Primitive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡